HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Department of Public and International Affairs, National Institute for Medical Research Development, Tehran, Iran.
Pharmacoepidemiol Drug Saf. 2021 Aug;30(8):1101-1114. doi: 10.1002/pds.5235. Epub 2021 May 2.
Underreporting of Adverse Drug Reactions (ADRs) reduces the sensitivity of pharmacovigilance systems. We described ADR reporting and its trend from 1999 to 2017 and estimated the ADR underreporting in the Iranian Pharmacovigilance Center.
We expressed the number of ADR reporting per inhabitants and admissions and their possible trends. Finally, ADR underreporting percentages were estimated by three approaches: prospective studies, literature review, stratification of the country; and the trend of the proportion of ADR per inhabitants was corrected.
The proportion of ADR reporting was 15.3 per 100 000 inhabitants (95% CI: 15.2, 15.8) and 10.0 per 100 000 admissions (95% CI: 9.8, 10.2) in 2017, and its trend was increasing with 16.3% average change per annum during 19 years. The median of estimated percentages of underreporting was 76.0% (IQR: 64.32-81.35). After the correction, the mean proportion of ADR reporting for 19 years reached from 5.87 to 10.33 per 100 000 inhabitants.
The trend of ADRs reporting has been increasing over the 19 years but is still low. This study showed a considerable underreporting of ADR, and about one of four detected ADRs were reported to the pharmacovigilance center from 1999 to 2017.
药物不良反应(ADR)漏报降低了药物警戒系统的敏感性。我们描述了 1999 年至 2017 年的 ADR 报告及其趋势,并估计了伊朗药物警戒中心的 ADR 漏报率。
我们表示了每 10 万居民和每 10 万住院患者的 ADR 报告数量及其可能的趋势。最后,通过三种方法估计了 ADR 漏报率:前瞻性研究、文献综述、国家分层;并校正了每 10 万居民中 ADR 比例的趋势。
2017 年,ADR 报告比例为每 10 万居民 15.3 例(95%CI:15.2,15.8)和每 10 万住院患者 10.0 例(95%CI:9.8,10.2),19 年间呈上升趋势,年均增长率为 16.3%。估计漏报率中位数为 76.0%(IQR:64.32-81.35)。校正后,19 年间 ADR 报告比例平均值从 5.87 上升至 10.33/10 万居民。
19 年间,ADR 报告趋势呈上升趋势,但仍较低。本研究表明 ADR 漏报率相当高,1999 年至 2017 年,约有四分之一的 ADR 报告给了药物警戒中心。